Cash, cash equivalents and investment securities were $199.5 million as of December 31, 2025. We anticipate that our cash, cash equivalents and investment securities as of December 31, 2025, combined with the projected revenues from BRIUMVI, will be sufficient to fund our business based on our current operating plan.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX:
- TGTX Upcoming Earnings Report: What to Expect?
- TG Therapeutics announces long-term data on Briumvi published in JAMA Neurology
- TG Therapeutics price target lowered to $46 from $49 at JPMorgan
- Buy Rating on Briumvi Driven by Strong Commercial Momentum, 2026 Growth Outlook, and Underappreciated Autoimmune Pipeline Optionality
- TG Therapeutics price target raised to $39 from $37 at Goldman Sachs